When do you recommend consolidative XRT for patients with advanced stage (III-IV) DLBCL who achieve CR to chemoimmunotherapy?

What XRT dose do you use? Does the location of the disease (e.g., mediastinum) affect your decision when taking toxicity into account? would you offer it to non-bulky disease?

Answer from: Radiation Oncologist at Academic Institution

The cornerstone of therapy for advanced DLBCL is chemoimmunotherapy (R-CHOP). Efforts to improve upon this with systemic therapy have been largely unsuccessful (dose-dense chemotherapy, maintenance R, more intensive chemotherapy, high-dose chemotherapy and autologous SCT, etc.). There are increasing...

Comments

Medical Oncologist at Florida Cancer Specialists and Research Institute
@Christopher R. Kelsey, Both UNFOLDER and RICOVER...

Answer from: at Academic Institution

In 31 years of practice, I have never seen a case with III-IV presentations and limited disease extent in which all sites of disease can be safely encompassed. Even if they existed, I believe no data exists to support RT in this setting, either as an addition to systemic therapy, or instead of syste...

Please select the option that best describes you:

When do you recommend consolidative XRT for patients with advanced stage (III-IV) DLBCL who achieve CR to chemoimmunotherapy?

Related Questions